Business Wire

Wallarm Reveals Current Threats to API Security, Move to 100% Channel Strategy and New API Attack Management Solution at Black Hat Europe 2023

Share

BLACK HAT EUROPE 2023 Wallarm, the integrated app and API security company, today announced its upcoming appearance at Black Hat Europe 2023, the Dec. 4 to Dec. 7 conference that provides the latest in research, development and trends in information security. Wallarm executives are hosting a session on Dec. 7 at 12:15 p.m. GMT at ExCeL London and sharing critical insights and recommendations from the latest API ThreatStats™ report. Additionally, Wallarm is discussing its new 100% channel strategy and launching a new API Attack Surface Management solution during Black Hat Europe.

Wallarm’s Black Hat appearance comes as interest in API security solutions grows in Europe, with the Europe API security market expected to witness market growth of 31.5% CAGR during the forecast period (2023-2030). This critical opportunity allows Wallarm to build awareness around the need for API and app security, jump-start expansion to the European market and recruit additional channel partners.

Key announcements from Wallarm include:

Latest discoveries in API security from ThreatStats™ report

Wallarm’s Tim Erlin, head of product, and Girish Bhat, VP of marketing, are leading the Black Hat Europe session, sharing real-time insights into threats from the latest API ThreatStats™ report, such as detection of 239 new vulnerabilities, injections and API data leaks. They’ll also recommend solutions to help security practitioners fortify their digital assets, such as prioritizing authentication, authorization and access control principles and integrating API leak protection measures.

New 100% channel model

The Wallarm team is also discussing its move to a 100% channel model. With a 100% channel strategy, Wallarm can deliver a better customer experience through its channel partners, ensuring customers get the best value from working with a trusted solution provider of their choice. With this announcement, Wallarm is focused on developing new partnerships globally among VARs, distributors and technology partners, as partner profitability and enablement are key parts of the expanding channel partner program. Wallarm’s channel partners include Google Cloud, Amazon Web Services, Microsoft Azure, security solutions leaders and independent software vendors.

“Our channel program is directly linked to the quality service we provide our customers, so our move to a 100% channel model is unique,” said Clay Speckmiear, head of channel at Wallarm. “As we look toward rapid growth, a 100% channel model will help us improve our efficiency and avoid channel conflict, while not sacrificing value for our customers.”

API Attack Surface Management product launch

During Black Hat Europe, Wallarm is launching API Attack Surface Management, which identifies APIs, hosts, risks and misconfigurations. The new product arrives as more organizations lack visibility into their public API attack surface, such as which APIs are exposed, what risks they exhibit and whether they’re protected. Existing solutions are limited and occasionally only partially solve the problem.

As part of the API Attack Surface Management launch, Wallarm is introducing its API Leak Detection capability, which identifies leaked secrets — essential amid the growing concern of API data leaks.

To learn more about Wallarm’s upcoming announcements, please visit the team during Black Hat Europe at booth #426 and attend the session in Business Hall Theater C.

To become a channel partner, please sign up at https://www.wallarm.com/partners.

To try API Attack Surface Management, please visit https://www.wallarm.com/.

About Wallarm

Wallarm, the integrated App and API Security company, provides robust protection for APIs, web applications, microservices, and serverless workloads running in cloud-native environments. Wallarm is the preferred choice of hundreds of Security and DevOps teams for comprehensive discovery of web apps and API endpoints, protection against emerging threats throughout their API portfolio, and automated incident response to enhance risk management. Our platform supports modern tech stacks, offering dozens of deployment options in cloud and Kubernetes-based environments, and also provides a full cloud solution. Wallarm is headquartered in San Francisco, California, and is backed by Toba Capital, Y Сombinator, Partech, and other investors.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Sara Black
PRforWallarm@bospar.com

Girish Bhat
girish@wallarm.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Daiichi Sankyo Announces the Initiation of the Development of Oral Triple Combination Lipid-Lowering Tablets to Support the Management of LDL-C30.8.2025 19:00:00 EEST | Press release

Daiichi Sankyo Europe is pleased to announce the initiation of the development of new oral triple combination tablets in Europe of bempedoic acid, ezetimibe, and different doses of a statin (atorvastatin or rosuvastatin), with the potential to lower low-density lipoprotein cholesterol (LDL-C) levels.9 It is well known that combination therapies reduce the pill burden for patients, potentially enhancing treatment adherence and facilitating treatment with a goal of improving cardiovascular outcomes.9,10 “As bempedoic acid and ezetimibe are already approved as a single-dose therapy, the development of an oral triple combination tablet with different doses of a statin, can make it easier for physicians to tailor treatment to the individual needs of each patient,” says Dr. Stefan Seyfried, Vice President and Head Medical Affairs Specialty Medicines, Daiichi Sankyo Europe. “This approach exemplifies our dedication to our motto: ‘we care for every heartbeat’.” “The management of dyslipidaemia

Alnylam to Advance Zilebesiran into Global Phase 3 Cardiovascular Outcomes Trial30.8.2025 17:30:00 EEST | Press release

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced plans to initiate a Phase 3 cardiovascular outcomes trial (CVOT) to evaluate the potential of zilebesiran to reduce the risk of major adverse cardiovascular events. This decision is informed by results from the comprehensive KARDIA Phase 2 program, including KARDIA-3 results presented today as a late-breaking abstract at the European Society of Cardiology (ESC) Congress in Madrid, Spain. Zilebesiran is an investigational subcutaneously administered RNAi therapeutic which, in the KARDIA Phase 2 program, has shown reductions in blood pressure by targeting liver-expressed angiotensinogen (AGT), the most upstream precursor in the Renin-Angiotensin-Aldosterone System (RAAS), which plays a key role in blood pressure regulation and impacts cardiovascular and renal health. KARDIA-3, the third Phase 2 study in the KARDIA program, evaluated the efficacy and safety of zilebesiran in patients with

BeOne Medicines Announces Positive Topline Results for Sonrotoclax in Relapsed or Refractory Mantle Cell Lymphoma (MCL)29.8.2025 13:00:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced positive topline results from a Phase 1/2 study (BGB-11417-201) of sonrotoclax, a next-generation and potentially best-in-class investigational BCL2 inhibitor, in adult patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL), following treatment with a Bruton’s tyrosine kinase inhibitor (BTKi) and anti-CD20 therapy. BeOne plans to present the full data at an upcoming medical meeting. “For people with relapsed or refractory mantle cell lymphoma, the disease is aggressive, the treatment landscape fragmented, and the outcomes unacceptably poor. These topline results for sonrotoclax underscore its potential to deliver meaningful and durable responses and offer the first BCL2 inhibitor for patients with R/R MCL, if approved,” said Lai Wang, PhD, Global Head of R&D, BeOne Medicines. “These data add to the remarkable progress we’ve seen over the past five years in treating B-cel

Oulu2026 – European Capital of Culture: Oulu to Unveil Full European Capital of Culture 2026 Programme – Live Stream on 4 September 202529.8.2025 11:46:00 EEST | Press release

Hundreds of partners are creating a year in which Northern Finland becomes a new hub of culture. The programme will offer something for everyone: large-scale exhibitions, festivals across all genres, world premieres, performing arts, village celebrations, permanent artworks, sports, and community events across a vast region of 40 municipalities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250829591577/en/ Oulu, with its 39 partner municipalities in Northern Finland, will step into the spotlight as European Capital of Culture 2026. The full programme will be officially launched on Thursday 4 September 2025 in Oulu, streamed live across Europe. The Oulu2026 programme is built around the theme of Cultural Climate Change, meaning a lasting enrichment of cultural life – connecting people through world-class experiences, creativity, and new ways of thinking. “2026 will be a transformative year – for our city, for Northern Finla

Nippon Sanso Holdings Group Unifies Global Brand Logo Launching the "NIPPON SANSO" Brand Worldwide29.8.2025 09:00:00 EEST | Press release

Nippon Sanso Holdings Corporation (President CEO: Toshihiko Hamada) will unify the brand logo for its industrial gas business globally and implement the change in stages. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250828253560/en/ Until now, our group has operated industrial gas businesses worldwide using the same symbol mark, while adapting to each region. To further enhance recognition and understanding of our group as a unified entity among a broad range of stakeholders, and to maximize corporate value and achieve sustainable growth, we have decided to unify the brand for our industrial gas businesses as "NIPPON SANSO" and standardize the brand logo globally. Moving forward, we will continue striving to be a trusted company for all stakeholders as a globally recognized brand. *Please note that Thermos Group, which operates the consumer household goods business within our group, will not change its brand logo. *The log

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye